Cefepime Dosing in Neonates: What is the Evidence?

Abstract

Objective Recommended cefepime dosing strategies in neonates varies in commonly utilized dosing references with regard to dose and frequency. The objective of this review is to summarize and evaluate the available literature describing cefepime dosing in neonatal patients.

Study Design We performed a literature review in MEDLINE using the keyword cefepime. The search was limited to the English language, humans, and patients <2 months of age. We evaluated four pharmacokinetic studies and two studies describing the use of cefepime in clinical practice.

Results The available studies assessing cefepime serum concentrations in neonatal patients demonstrated maintenance of adequate pharmacokinetic parameters when utilizing a dosing frequency of every 12 hours, specifically for organisms with a minimum inhibitory concentration (MIC) ≤ 8 mg/L. In studies evaluating clinical outcomes of cefepime use in neonates, the most frequent adverse effects reported included seizures and hypophosphatemia. Microbiologic cure was demonstrated with a dosing regimen of 50 mg/kg per dose every 12 hours.

Conclusion Cefepime dosed 30 to 50 mg/kg per dose every 12 hours may be appropriate to achieve a concentration two to four times above an MIC ≤ 8 mg/L for at least 60% of the dosing interval in neonatal patients.

Keywords

cefepime - cephalosporins - infant - newborn - pharmacokinetics - antibacterial agents - drug monitoring - Pseudomonas

Publication History

Received: 31 July 2019

Accepted: 07 October 2019

Article published online:
27 November 2019

• References

• 1 Maxipime (cefepime hydrochloride, USP) for injection. Accessed October 21, 2019 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf
• 2 Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther 2014; 19 (04) 262-276
• 3 Clinical and Laboratory Standards Institute (CLSI). M100. Performance Standards for Antimicrobial Susceptibility Testing, 29th edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2019
• 4 Cefepime. Neofax. Truven Health Analytics, Inc.; Ann Arbor, MI: . Accessed July 14, 2019 at: http://www.micromedexsolutions.com
• 5 American Academy of Pediatrics. Tables of Antibacterial Drug Dosages. In: Kimberlin DW, Brady MT, Jackson MA, Long SS. eds. Red Book (2018): Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018
• 6 Cefepime. Pediatric and Neonatal Lexi-Drugs Online. Lexicomp. Wolters Kluwer Health, Inc.; Riverwoods, IL: . Accessed July 14, 2019 at: http://online.lexi.com
• 7 Kliegman RM, Stanton B, St Geme J, Schor NF. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2015
• 8 Megan T, Kristin A. eds. The Harriet Lane handbook: A Manual for Pediatric House Officers. Philadelphia, PA: Mosby Elsevier; 2012
• 9 Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005; 49 (07) 2760-2766
• 10 Ellis JM, Rivera L, Reyes G. et al. Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis. Ann Pharmacother 2007; 41 (05) 900-901
• 11 Lima-Rogel V, Medina-Rojas EL, Del Carmen Milán-Segovia R. et al. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections. J Clin Pharm Ther 2008; 33 (03) 295-306
• 12 Shoji K, Bradley JS, Reed MD, van den Anker JN, Domonoske C, Capparelli EV. Population pharmacokinetic assessment and pharmacodynamics implications of pediatric cefepime dosing for susceptible-dose-dependent organisms. Antimicrob Agents Chemother 2016; 60 (04) 2150-2156
• 13 Arnold CJ, Ericson J, Cho N. et al; Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee. Cefepime and ceftazidime safety in hospitalized infants. Pediatr Infect Dis J 2015; 34 (09) 964-968
• 14 Knoderer CA, Kaylor DM, Toth ME, Malloy KM, Nichols KR. Characterization of the clinical outcomes with cefepime in a neonatal intensive care unit: a retrospective cohort study. J Pediatr Pharmacol Ther 2018; 23 (03) 209-214
• 15 Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin Jr. DK, Smith PB. Best Pharmaceuticals for Children Act—Pediatric Trials Network. Medication use in the neonatal intensive care unit. Am J Perinatol 2014; 31 (09) 811-821
• 16 Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009; 53 (03) 379-385
• 17 Beauchamp LC, Nichols KR, Knoderer CA. Outcomes of extended infusion cefepime in pediatric patients. Infect Dis Clin Pract 2019; 27: 283-287
• 18 Boschung-Pasquier L, Atkinson A, Kastner LK. et al. Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect 2019;
• 19 El Bashir H, Laundy M, Booy R. Diagnosis and treatment of bacterial meningitis. Arch Dis Child 2003; 88 (07) 615-620